Arbutus Biopharma Corporation (ABUS) P/E Ratio History
Historical price-to-earnings valuation from 2012 to 2013
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, Arbutus Biopharma Corporation (ABUS) trades at a price-to-earnings ratio of -12.3x, with a stock price of $4.66 and trailing twelve-month earnings per share of $-0.22.
The current P/E is 564% below its 5-year average of 2.6x. Over the past five years, ABUS's P/E has ranged from a low of 2.2x to a high of 3.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, ABUS trades at a 152% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, ABUS trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ABUS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. RNA and Genome Editing Developers peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ALNYAlnylam Pharmaceuticals, Inc. | $44B | 142.9 | -Best | +207% |
SLXNWSilexion Therapeutics Ltd. | $64M | 0.0Lowest | -Best | +6436%Best |
DTILPrecision BioSciences, Inc. | $51M | 4.0 | -Best | +107% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2013 Q3 | Mon Sep 30 2013 00:00:00 GM | $6.95 | $1.90 | 3.7x | +38% |
| FY2013 Q2 | Sun Jun 30 2013 00:00:00 GM | $4.70 | $2.06 | 2.3x | -14% |
| FY2013 Q1 | Sun Mar 31 2013 00:00:00 GM | $4.71 | $2.12 | 2.2x | -16% |
| FY2012 Q4 | Mon Dec 31 2012 00:00:00 GM | $4.96 | $2.05 | 2.4x | -9% |
Average P/E for displayed period: 2.6x
See ABUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABUS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ABUS vs AGIO
See how ABUS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ABUS stock overvalued or undervalued?
ABUS trades at -12.3x P/E, below its 5-year average of 2.6x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does ABUS's valuation compare to peers?
Arbutus Biopharma Corporation P/E of -12.3x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is ABUS's PEG ratio?
ABUS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2012-2013.